06/22/22 4:01 PMNasdaq : DRTS Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the first patient was treated in a feasibility study evaluating the Alpha DaRT as a neoadjuvant therapy inRHEA-AIneutral
06/16/22 4:01 PMNasdaq : DRTS Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended Radioactive License with Increased Capacity at Lawrence, MA SiteAlpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that the Israeli Ministry of Environmental Protection has granted the Company an activeRHEA-AIvery positive
06/08/22 9:10 AMNasdaq : DRTS fda approvalAlpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCCAlpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved theRHEA-AIvery positive
06/07/22 4:03 PMNasdaq : DRTS managementAlpha Tau Announces Resignation of Gary Leibler from its Board of DirectorsAlpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Mr. Gary Leibler has resigned from the Company's board of directors andRHEA-AIneutral
05/26/22 4:05 PMNasdaq : DRTS earningsAlpha Tau Medical Announces First Quarter 2022 Financial Results and Provides Corporate UpdateAlpha Tau Medical Ltd. (NASDAQ:RHEA-AIneutral
05/23/22 9:00 AMNasdaq : DRTS First Alpha DaRT Patients Treated in France as Part of Alpha DaRT™ Multicenter Skin Cancer TrialAlpha Tau Medical (Nasdaq: DRTS) (Nasdaq: DRTSW) , the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT™, announced today that the first patients in its French multicenter trial for skin cancer were treated with Alpha DaRT, at the LeonRHEA-AIneutral
03/28/22 8:00 AMNasdaq : DRTS, DRTSW earningsAlpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate UpdateAlpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported full year 2021 financial results and provided a corporate update."We have had anRHEA-AIneutral
